## Halocarbocyclization Entry into the Oxabicyclo[4.3.1]decyl Exomethylene- $\delta$ -Lactone Cores of Linearifolin and Zaluzanin A: Exploiting Combinatorial Catalysis


## Sandeep K. Ginotra, Jacob A. Friest, and David B. Berkowitz\*

Department of Chemistry, University of Nebraska, Lincoln, Nebraska 68588-0304, United States

dbb@unlserve.unl.edu

## Received November 17, 2011

## ABSTRACT



A streamlined entry into the sesquiterpene lactone (SQL) cores of linearifolin and zaluzanin A is described. Stereochemistry is controlled through transformations uncovered by ISES (In Situ Enzymatic Screening). Absolute stereochemistry derives from kinetic resolution of 5-benzyloxypentene-1,2-oxide, utilizing a  $\beta$ -pinene-derived-Co(III)-salen. Relative stereochemistry (1,3-cis-fusion) is set via formal halometalation/carbocyclization, mediated by [Rh(O<sub>2</sub>CC<sub>3</sub>F<sub>7</sub>)<sub>2</sub>]<sub>2</sub>/LiBr. Subsequent ring-closing metathesis (RCM-Grubbs II) yields the title exomethylene- $\delta$ -lactone SQL cores. In complementary fashion, RCM with Grubbs-I catalyst provides the oxabicyclo[3.3.1]nonyl core of xerophilusin R and zinagrandinolide.

ISES (In Situ Enzymatic Screening)-assisted catalyst development has led to the (i) discovery of the first asymmetric Ni(0)-mediated allylic amination chemistry,<sup>1</sup> (ii) new halometalation/carbocyclization transformations,<sup>2</sup> and (iii) the identification of novel chiral salen ligands for asymmetric catalysis.<sup>3</sup> This Letter describes the deployment of the latter two methods for stereocontrolled entry into bicyclic terpenoid natural product (NP) cores bearing a reactive exomethylene  $\delta$ -lactone functionality.

This functional group has been linked to NFKB-inhibition via active site cysteine capture, leading Merfort to propose a QSAR model for NFKB inhibition/anticancer activity in such sesquiterpene lactones (SQLs).<sup>4</sup> Against this medicinal chemistry backdrop there has been vigorous synthetic activity in the exomethylene SQL area,<sup>5</sup> including approaches that permit core synthesis<sup>6</sup> and chain extension.<sup>7</sup> While a number of routes focus on end game methylenation,<sup>8</sup> we favored a convergent strategy in which a formal halometalation/carbocyclization would at once close the lactone, control ring fusion geometry, and set in

ORGANIC LETTERS

2012 Vol. 14, No. 4

968-971

<sup>(1) (</sup>a) Berkowitz, D. B.; Shen, W.; Maiti, G. *Tetrahedron: Asymmetry* **2004**, *15*, 2845–2851. (b) Berkowitz, D. B.; Maiti, G. *Org. Lett.* **2004**, *6*, 2661–2664. (c) Berkowitz, D. B.; Bose, M.; Choi, S. *Angew. Chem., Int. Ed.* **2002**, *41*, 1603–1607.

<sup>(2)</sup> Friest, J. A.; Broussy, S.; Chung, W. J.; Berkowitz, D. B. Angew. Chem., Int. Ed. 2011, 50, 8895–8899.

<sup>(3) (</sup>a) Dey, S.; Powell, D. R.; Hu, C.; Berkowitz, D. B. Angew. Chem., Int. Ed. 2007, 46, 7010–7014. (b) Dey, S.; Karukurichi, K. R.; Shen, W.; Berkowitz, D. B. J. Am. Chem. Soc. 2005, 127, 8610–8611.

<sup>(4) (</sup>a) Merfort, I. *Curr. Drug Targets* **2011**, *12*, 1560–1573. (b) Wagner, S.; Hofmann, A.; Siedle, B.; Terfloth, L.; Merfort, I.; Gasteiger, J. J. Med. Chem. **2006**, *49*, 2241–2252.

<sup>(5) (</sup>a) Kalidindi, S.; Jeong Won, B.; Schall, A.; Bandichhor, R.; Nosse, B.; Reiser, O. *Angew. Chem., Int. Ed.* **2007**, *46*, 6361–6363. (b) Edwards, M. G.; Kenworthy, M. N.; Kitson, R. R. A.; Scott, M. S.; Taylor, R. J. K. *Angew. Chem., Int. Ed.* **2008**, *47*, 1935–1937. (c) Kummer, D. A.; Brenneman, J. B.; Martin, S. F. *Org. Lett.* **2005**, *7*, 4621–4623. (d) Hodgson, D. M.; Talbot, E. P. A; Clark, B. P. *Org. Lett.* **2011**, *13*, 5751–5753.

<sup>(6)</sup> Nosse, B.; Chhor, R. B.; Jeong, W. B.; Boehm, C.; Reiser, O. Org. Lett. 2003, 5, 941–944.

<sup>(7) (</sup>a) Han, C.; Barrios, F. J.; Riofski, M. V.; Colby, D. A. J. Org. Chem. **2009**, 74, 7176–7179. (b) Moiese, J.; Arseniyadis, S.; Cossy, J. Org. Lett. **2007**, 9, 1695–1698.




Figure 1. Targeted oxabicyclo[4.3.1]decyl SQL cores.





Figure 2. Retrosynthetic analysis.

place the reactive, conjugated exomethylene moiety.<sup>2</sup> This approach has an added benefit for chemical biology, as the resultant  $\beta$ -bromo- $\alpha$ ,  $\beta$ -unsaturated carbonyl system should be advantageous for library generation.<sup>9</sup>

Targeted herein are the cores of SQLs carrying this functionality within a bridged oxabicyclo[4.3.1]decyl framework, as in linearifolin angelate<sup>10</sup> (Figure 1; from *H. linearifolium*,



**Figure 3.** ISES readout on salen-set/new reporting enzymes. ISES screens for sense (+ S; - R) and magnitude of enantiopreference for Co(III)-salen-mediated HKR with hexene oxide (purple) and propylene oxide (green) and 1,2-Diamines:<sup>3a</sup> 4 ( $\beta$ pinene-derived); 5 (L- $\beta$ -naphthyl-Ala-derived); 6 (L-Phe-derived); 7 (L-phenyl-Gly-derived). Hydroxybenzaldehydes: a ( $\alpha$ -hydroxy- $\beta$ -naphthaldehyde); b (3,5-diiodosalicylaldehyde); c (3-*t*-Busalicylaldehyde); d (3,5-di-*t*-Bu-salicylaldehyde). Note: For entries 4c, 5b,c, 6a-d, and 7a-d new reporting enzymes (KRED (Ketoreductase) 107 *S*-selective; KRED 119 *R*-selective) for the HKR of hexene oxide were employed.

related to fastigilin A, a potent antineoplastic agent)<sup>11</sup> and zaluzanin A (muscle relaxant).<sup>12</sup>

Interestingly, these two terpenoid lactone cores have opposite handedness; therefore efficient hydrolytic kinetic resolution  $(HKR)^{3,13}$  should allow for assembly of both cores from a common racemic epoxide building block precursor (Figure 2), one from the diol product (as the cyclic sulfate), the other from the remaining epoxide. Such a convergent sequence would both allow for the efficient assembly of the exomethylene  $\delta$ -lactone and set the cis-1,3-fusion stereochemistry in the key halometalation carbocyclization step, a transformation for which both Rh-perfluorocarboxylate and Pd(II) catalysts have been uncovered recently in our lab.<sup>2,14</sup>

Toward this end, an improved ISES screen [Figure 3, new KRED (ketoreductase) enzymes<sup>15</sup>] identified the salen **4a** catalyst, assembled from the  $\beta$ -pinene-derived diamine and  $\alpha$ -hydroxy- $\beta$ -naphthaldehyde, in its Co(III)-OAc form as a generally (*S*)-selective catalyst for terminal epoxides. This KRED assay has advantages over the previously reported hexene oxide screen,<sup>3a</sup> as the two reporting enzymes show opposite enantioselectivities (see Supporting Information) and both are readily available. For the synthesis at hand, efficient HKR of an *O*-protected

<sup>(8) (</sup>a) Riofski, M. V.; John, J. P.; Zheng, M. M.; Kirshner, J.; Colby, D. A. *J. Org. Chem.* **2011**, *76*, 3676–3683. (b) For an elegant Pauson–Khand entry into the related guaianolides, that introduces the  $\alpha$ -methylene lactone at an early stage, see: Grillet, F.; Huang, C.; Brummond, K. M. *Org. Lett.* **2011**, *13*, 6304–6307.

<sup>(9) (</sup>a) Basu, S.; Ellinger, B.; Rizzo, S.; Deraeve, C.; Schurmann, M.; Preut, H.; Arndt, H.-D.; Waldmann, H. *Proc. Natl. Acad. Sci. U.S.A.* **2011**, *108*, 6805–6810. (b) Dekker, F. J.; Koch, M. A.; Waldmann, H. *Curr. Opin. Chem. Biol.* **2005**, *9*, 232–239.

<sup>(10)</sup> Zdero, C.; Bohlmann, F.; Boldt, P. E. *Phytochemistry* **1991**, *30*, 1585–1590.

<sup>(11)</sup> Pettit, G. R.; Herald, C. L.; Gust, D.; Herald, D. L.; Vanell, L. D. J. Org. Chem. 1978, 43, 1092–5.


<sup>(12)</sup> Van Calsteren, M.-R.; Jankowski, C. K.; Reyes-Chilpa, R.; Jimenez-Estrada, M.; Campos, M. G.; Zarazua-Lozada, A.; Oropeza, M.; Lesage, D. *Can. J. Chem.* **2008**, *86*, 1077–1084.

<sup>(13) (</sup>a) Fang, Y.-Q.; Jacobsen, E. N. J. Am. Chem. Soc. 2008, 130, 5660–5661. (b) Nielsen, L. P. C; Stevenson, C. P.; Blackmond, D. G.; Jacobsen, E. N. J. Am. Chem. Soc. 2004, 126, 1360–1362. (c) Schaus, S. E.; Brandes, B. D.; Larrow, J. F.; Tokunaga, M.; Hansen, K. B.; Gould, A. E.; Furrow, M. E.; Jacobsen, E. N. J. Am. Chem. Soc. 2002, 124, 1307–1315.

 <sup>(14) (</sup>a) Zhang, Q.; Lu, X.; Han, X. J. Org. Chem. 2001, 66, 7676–7684. (b) Zhu, G.; Lu, X. Organometallics 1995, 14, 4899–4904.


<sup>(15)</sup> Broussy, S.; Cheloha, R. W.; Berkowitz, D. B. Org. Lett. 2009, 11, 305–308.

Table 1. HKR of AcO-Co(III)-4a across Potential Synthons<sup>a</sup>



<sup>*a*</sup> Conditions: 1.3 mmol of epoxide; 0.67 mmol of  $H_2O$  in 100  $\mu$ L of THF, with 2.5 mol % Co(III)-salen derived from **4a**. Conversion estimated by NMR and ee by HPLC-chiral stationery phase (Supporting Information).


Scheme 1. HKR (Salen 4a) Provides Both SQL Building Blocks





5-hydroxy-1,2-pentene oxide was desired. Accordingly, a series of such potential building blocks were screened for HKR with Co(III)-4a-OAc. As can be seen (Table 1), this catalyst is generally (*S*)-selective for substrates bearing arylmethyl ether protecting groups.

In the event, when racemic **9** was treated with Co(III)-**4a**-OAc, on a 13 g scale, both antipodal building blocks, (*R*)-epoxide **9b** and (*S*)-diol **12**, were obtained in high ee (Scheme 1) attesting to the potential<sup>3a</sup> of this new chiral salen in asymmetric catalysis. The diol was easily converted to the corresponding cyclic sulfate **13**.

As is illustrated in Scheme 2, the requisite 3-carbon allylic carbonate "acceptor" functionality for the carbocyclization could be installed via cyclic sulfate opening with a lithiated propargyl ether. Lindlar semihydrogenation and unveiling of the masked terminal olefin were followed by selective carbonylation of the primary alcohol. The propiolate moiety then enters with Mitsunobu inversion at the HKR-derived stereocenter. Scheme 2. Convergent Assembly of the Halometalation/ Carbocyclization Substrate








The title bromorhodiation/carbocylization was carried out on 18a,<sup>2</sup> crafting both the Z-configured C-Br bond and the ring-forming C-C bond, thereby setting in place the requisite cis-1,3-ring fusion in 19a. Moreover, a detailed study (50 mg scale) showed that yields could be increased to >90%, with 5 mol % catalyst, by reducing the temperature and increasing the reaction time (Supporting Information). Note that this formal halometalation/carbocyclization bears

<sup>(16) (</sup>a) Ma, S.; Lu, L.; Zhang, J. J. Am. Chem. Soc. **2004**, *126*, 9645–9660. (b) Lei, A.; Waldkirch, J. P.; He, M.; Zhang, X. Angew. Chem., Int. Ed. **2002**, *41*, 4526–4529.


Scheme 4. (R)-Epoxide Leads into the Zaluzanin A Core



some resemblance, particularly in the product structure, to Rh(I)-mediated carbocyclizations reported by Zhang that involve formal Alder-ene alkyne/allyl C-H cycloisomerization<sup>16</sup> or alkyne/allylic C-Cl condensation, with an accompanying halide shift.<sup>17</sup> The vinyl halide geometry obtained here is opposite that found in the Zhang chemistry, and both the Rh catalyst (Rh(II)-perfluorocarboxylate/LiBr) and educts (allylic carbonates) employed here also differ.

Subsequent ring-closing metathesis (RCM, Grubbs II catalyst)<sup>18</sup> closes the bicyclo[4.3.1]decenyl linearifolin core. The 3D-structure of the core was solved by X-ray crystallography which also served to confirm absolute stereochemistry (Scheme 3). The antipodal series follows from the (R)epoxide obtained in the initial HKR of 5-benzyloxy-pentene oxide mediated by Co(III)-4a-OAc (Scheme 1). The sequence mirrors that described for entry into the linearfolin core with the exception that epoxide 9b, rather than a cyclic sulfate, is opened by the lithiated propargyl ether, a reaction found to proceed optimally in the presence of  $F_3B-OEt_2$ (Scheme 4). Here too, X-ray crystallography established 3D structure and absolute stereochemistry.

In the course of this investigation, it was also discovered that one could gain access to ring contracted cores by RCM modification. Olefin isomerization is known to occasionally accompany metathesis, presumably via the intermediacy of Scheme 5. Isomerization–RCM: Oxabicyclo[3.3.1]nonyl Cores of Zinagrandinolide/Xerophilusin R



Ru–H species, as studied by Schmidt,<sup>19</sup> Grubbs,<sup>20</sup> and Snapper.<sup>21</sup> This serves as an added benefit of this synthetic route, with the Grubbs I catalyst<sup>22</sup> giving ring contraction, and thereby access, to the oxabicyclo[3.3.1]nonyl core in zinagrandinolide<sup>23</sup> and xerophilusin R<sup>24</sup> (Scheme 5), both antineoplastic natural products.<sup>23,24</sup> Future studies will be directed at the further exploration of this promising  $\beta$ pinene-based salen scaffold in asymmetric catalysis, and this versatile halocarbocyclization transformation, and at the deployment of these NP cores in chemical biology.

Acknowledgment. The NSF (CHE-0911732) is acknowledged for support. Xiang Fei and Robert A. Swyka are thanked for assistance. Douglas Powell (U. of Oklahoma) is acknowledged for X-ray structures. D.B.B. currently serves as a Program Director at the NSF. This research was facilitated by the IR/D (Individual Research and Development) program associated with that appointment. The authors thank the NIH (SIG-1-510-RR-06307)/ NSF (CHE-0091975, MRI-0079750) (NMR) and NIH (RR016544) (facilities).

**Supporting Information Available.** Experimental details, characterization, NMR spectra, and HPLC traces. This material is available free of charge via the Internet at http://pubs.acs.org.

<sup>(17) (</sup>a) Tong, X.; Li, D.; Zhang, Z.; Zhang, X. J. Am. Chem. Soc. **2004**, *126*, 7601–7607. (b) Tong, X.; Zhang, Z.; Zhang, X. J. Am. Chem. Soc. **2003**, *125*, 6370–6371.

<sup>(18)</sup> Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953–956.

<sup>(19)</sup> Schmidt, B. Eur. J. Org. Chem. 2004, 1865–1880.

<sup>(20)</sup> Hong, S. H.; Sanders, D. P.; Lee, C. W.; Grubbs, R. H. J. Am. Chem. Soc. 2005, 127, 17160–17161.

<sup>(21) (</sup>a) Finnegan, D.; Seigal, B. A.; Snapper, M. L. Org. Lett. **2006**, *8*, 2603–2606. (b) Sutton, A. E.; Seigal, B. A.; Finnegan, D. F.; Snapper, M. L. J. Am. Chem. Soc. **2002**, *124*, 13390–13391.

<sup>(22)</sup> Schwab, P.; Grubbs, R. H.; Ziller, J. W. J. Am. Chem. Soc. 1996, 118, 100–110.

<sup>(23)</sup> Bashyal, B. P.; McLaughlin, S. P.; Gunatilaka, A. A. L. J. Nat. Prod. 2006, 69, 1820–1822.

<sup>(24)</sup> Niu, X.-M.; Li, S.-H.; Na, Z.; Lin, Z.-W.; Sun, H.-D. Helv. Chim. Acta 2004, 87, 1951–1957.

The authors declare no competing financial interest.